What question did this study set out to answer?

To assess early clinical response at day 3 with ceftaroline fosamil monotherapy compared with vancomycin plus aztreonam in patients treated for acute bacterial skin and skin structure infections.

February 7, 2012Antimicrobial Agents and ChemotherapyOpen Access

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections

View Full Paper

Ask AI

Bookmark

Authors

HFH. David FriedlandWockhardt (United States)TOTanya O’NealJohns Hopkins University DBDonald BiekApple (Israel)

Discussion

Member takes

Implication

Retrospective analysis of randomized trials reveals higher day 3 response with ceftaroline fosamil in bacterial skin infections, indicating effective early clinical resolution.

Key Points

To assess early clinical response at day 3 with ceftaroline fosamil monotherapy compared with vancomycin plus aztreonam in patients treated for acute bacterial skin and skin structure infections.
Conducted a retrospective analysis of two phase 3 trials (CANVAS 1 and 2) in adults with acute bacterial skin and skin structure infections and lesion sizes ≥ 75 cm².
Evaluated intravenous ceftaroline fosamil (600 mg every 12 h) versus vancomycin (1 g) plus aztreonam (1 g) every 12 h for 5 to 14 days, defining day 3 response as stopped infection spread and no fever.
Integrated day 3 clinical response rates reached 74.0% (296/400) for ceftaroline fosamil versus 66.2% (263/397) for vancomycin plus aztreonam (difference, 7.8%; 95% CI, 1.3% to 14.0%).
Absolute treatment differences favored ceftaroline fosamil across both individual trials by 9.4% in CANVAS 1 and 5.9% in CANVAS 2.
In infections caused by methicillin-resistant Staphylococcus aureus, day 3 clinical response rates were 81.7% with ceftaroline fosamil and 77.4% with vancomycin plus aztreonam.

Cite This Study

Friedland et al. (2012) studied this question.

synapsesocial.com/papers/6a956db625f7ee1b82332292 https://doi.org/10.1128/aac.05738-11

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis of randomized trials reveals higher day 3 response with ceftaroline fosamil in bacterial skin infections, indicating effective early clinical resolution.

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections

Discussion

Member takes

Implication

Key Points

Cite This Study

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider